India Glycols Limited has submitted to the Exchange, the financial results for the period ended Jun 30, 2025.
INDIAGLYCO · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
India Glycols reported its Q1 FY26 (quarter ended June 30, 2025) results with standalone revenue from operations at ₹2,503.03 cr, up about 9.7% from ₹2,282.43 cr in Q1 FY25. Standalone profit after tax rose to ₹52.66 cr from ₹46.78 cr, while EPS stood at ₹17.07 vs ₹15.10. On a consolidated basis, revenue was ₹2,503.12 cr and PAT was ₹73.25 cr (vs ₹60.38 cr), boosted by an ₹18.62 cr share of profit from joint venture Clariant IGL Specialty Chemicals. EBITDA margin expanded to about 6% from ~5.5% YoY on a standalone basis, reflecting improved operating efficiency. Statutory auditors K.N. Gutgutia & Co. issued an unqualified limited review report. The Board also noted updates on the Composite Scheme of Arrangement (Demerger of Bio Pharma and Spirits & Biofuel businesses) and the approved 1:2 stock split, with record date set for August 12, 2025.
Modest top-line growth with margin expansion and a clean auditor review are positive signals for shareholders. The stock split (effective Aug 12) will improve liquidity and affordability, while the proposed demerger could unlock value over time. Near-term stock reaction likely to be driven by the steady earnings show, with limited negative triggers.